Human CBR1 ELISA Kit (V2LY-0626-LY5553)

Go to compare Compare Online Inquiry
Tested Data
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Sensitivity
0.0093 ng/mL
Detection Range
0.02-4.5 ng/mL
Sample Type
Serum, Plasma, cell culture supernates
Specificity
Human
Assay Type
Sandwich
Reactivity
Human
Assay Time
1.5 h
Molecule Mass
30.4 kDa
Components
  • Pre-coated ELISA plate: 12 wells * 8 detachable strips
  • Standard solution: 0.5ml x1
  • Standard diluent: 3ml x1
  • Streptavidin-HRP: 6ml x1
  • Stop solution: 6ml x1
  • Substrate solution A: 6ml x1
  • Substrate solution B: 6ml x1
  • Wash buffer concentrate (25x): 20ml x1
  • Biotinylated antibody: 1ml x1

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 2-8°C
More Infomation

Target

Full Name
Carbonyl Reductase 1
Function
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:18449627, PubMed:15799708, PubMed:17912391, PubMed:7005231).
Can convert prostaglandin E to prostaglandin F2-alpha (By similarity).
Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:18826943, PubMed:17344335).
Biological Process
Cyclooxygenase pathway Source: Reactome
Drug metabolic process Source: UniProtKB
Epithelial cell differentiation Source: UniProtKB
Positive regulation of reactive oxygen species metabolic process Source: UniProtKB
Vitamin K metabolic process Source: UniProtKB
Cellular Location
Cytoplasm

Mao, L., Wang, K., Zhang, P., Ren, S., Sun, J., Yang, M., ... & Sun, B. (2021). Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation. Translational Stroke Research, 1-14.

Bell, R. M., Villalobos, E., Nixon, M., Miguelez-Crespo, A., Murphy, L., Fawkes, A., ... & Morgan, R. A. (2021). Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice. Molecular metabolism, 48, 101225.

Yun, M., Choi, A. J., Woo, S. R., Noh, J. K., Sung, J. Y., Lee, J. W., & Eun, Y. G. (2020). Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through β-catenin-Mediated Epithelial-Mesenchymal Transition. Journal of Cancer, 11(3), 533.

Koczurkiewicz-Adamczyk, P., Piska, K., Gunia-Krzyżak, A., Bucki, A., Jamrozik, M., Lorenc, E., ... & Pękala, E. (2020). Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells–Involvement of carbonyl reductase 1. European Journal of Pharmaceutical Sciences, 154, 105511.

Kajimura, T., Sato, S., Murakami, A., Hayashi‑Okada, M., Nakashima, K., Sueoka, K., & Sugino, N. (2019). Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF‑β signaling in uterine leiomyosarcoma cells. Oncology letters, 18(2), 1503-1512.

Seliger, J. M., Martin, H. J., Maser, E., & Hintzpeter, J. (2019). Potent inhibition of human carbonyl reductase 1 (CBR1) by the prenylated chalconoid xanthohumol and its related prenylflavonoids isoxanthohumol and 8-prenylnaringenin. Chemico-biological interactions, 305, 156-162.

Piska, K., Koczurkiewicz, P., Wnuk, D., Karnas, E., Bucki, A., Wójcik-Pszczoła, K., ... & Pękala, E. (2019). Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells–the involvement of carbonyl reductase 1 inhibition. Chemico-biological interactions, 300, 40-48.

Yun, M., Choi, A. J., Lee, Y. C., Kong, M., Sung, J. Y., Kim, S. S., & Eun, Y. G. (2018). Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research, 37(1), 1-12.

Yamanouchi, R., Harada, K., Ferdous, T., & Ueyama, Y. (2018). Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma. Molecular and clinical oncology, 8(3), 400-406.

Shi, S. M., & Di, L. (2017). The role of carbonyl reductase 1 in drug discovery and development. Expert opinion on drug metabolism & toxicology, 13(8), 859-870.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Human CBR1 ELISA Kit?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.